Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in the diagnostic setting. Comparatively less invasive than traditional solid tissue biopsy approaches, liquid biopsy specimens such as blood or urine can be used not only for early detection, but for the monitoring of therapeutic response and progression. While custom circulating tumor DNA (ctDNA) assays are being academically developed for the profiling of specific biomarkers in a specific disease or therapeutic context, there are commercially available pan-cancer circulating nucleic acid (cNA) panels available. These commercially available panels can be readily used to reveal the spectrum of key genomic changes within liquid biopsies, determine the level of sensitivity that can be obtained and provide a means for validation. This presentation will summarize the evaluation of the Oncomine Pan-Cancer Cell Free Assay and together with the Oncomine Comprehensive Assay v3 we demonstrate the utility of this platform to map nucleic acids released to the blood or urine in the context of breast and prostate cancer.
1. Define liquid biopsy profiling potential for improved cancer clinical management
2. Define liquid biopsy profiling provides insight on tumour progression